Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APOLLO ENDOSURGERY, INC.

(APEN)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
9.830 USD   -0.20%
01/23Cowen Downgrades Apollo Endosurgery to Market Perform From Outperform, Adjusts Price Target to $10 From $13
MT
01/05North American Morning Briefing: Futures Dip As a -2-
DJ
01/04Stifel Downgrades Apollo Endosurgery to Hold From Buy, Price Target is $10
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Apollo Endosurgery Shares Hit 52-Week High on Boston Scientific Deal

11/29/2022 | 10:51am EST

By Colin Kellaher


Shares of Apollo Endosurgery Inc. surged to a 52-week high on Tuesday after the medical-technology company agreed to be acquired by Boston Scientific Corp. in a cash deal valued at about $615 million.

Apollo investors will receive $10 a share in the deal, a 67% premium to Monday's closing price of $6.

Shares of the Austin, Texas, company were recently changing hands at $9.87, up nearly 65%, after hitting a 52-week high of $9.88 earlier in the session.

Marlborough, Mass., medical-device maker Boston Scientific said the Apollo deal adds to its portfolio of endoluminal surgery devices.

Analysts at Needham, who have a buy recommendation on Boston Scientific shares, said in a research note that the acquisition leverages the company's gastroenterologist call point while offering expansion potential into surgical endoscopy and bariatric surgery.

Shares of Boston Scientific, which expects to complete the acquisition of Apollo in the first half of 2023, edged up 0.8% to $44.16.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

11-29-22 1051ET

Stocks mentioned in the article
ChangeLast1st jan.
APOLLO ENDOSURGERY, INC. -0.20% 9.83 Delayed Quote.-1.40%
BOSTON SCIENTIFIC CORPORATION -0.95% 45.91 Delayed Quote.0.17%
All news about APOLLO ENDOSURGERY, INC.
01/23Cowen Downgrades Apollo Endosurgery to Market Perform From Outperform, Adjusts Price Ta..
MT
01/05North American Morning Briefing: Futures Dip As a -2-
DJ
01/04Stifel Downgrades Apollo Endosurgery to Hold From Buy, Price Target is $10
MT
2022Apollo Endosurgery, Inc. : Unregistered Sale of Equity Securities (form 8-K)
AQ
2022Apollo Endosurgery : Merger Agreement - Form 8-K
PU
2022Apollo Endosurgery, Inc. : Other Events (form 8-K)
AQ
2022Apollo Endosurgery To Be Acquired By Boston Scientific
AQ
2022North American Morning Briefing: Stock Futures -2-
DJ
2022Lake Street Downgrades Apollo Endosurgery to Hold From Buy, Adjusts Price Target to $10..
MT
2022Apollo Endosurgery, Inc. : Entry into a Material Definitive Agreement, Financial Statement..
AQ
More news
Analyst Recommendations on APOLLO ENDOSURGERY, INC.
More recommendations
Financials (USD)
Sales 2022 75,4 M - -
Net income 2022 -39,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -10,1x
Yield 2022 -
Capitalization 467 M 467 M -
Capi. / Sales 2022 6,20x
Capi. / Sales 2023 5,24x
Nbr of Employees 202
Free-Float 92,2%
Chart APOLLO ENDOSURGERY, INC.
Duration : Period :
Apollo Endosurgery, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APOLLO ENDOSURGERY, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 9,83 $
Average target price 11,00 $
Spread / Average Target 11,9%
EPS Revisions
Managers and Directors
Charles S. McKhann President, Chief Executive Officer & Director
Jeffrey G. Black Chief Financial Officer, Secretary & Treasurer
John R. Barr Chairman
Christopher J. Gostout Chief Medical Officer
Tiffanie Gilbreth Vice President-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
APOLLO ENDOSURGERY, INC.-1.40%467
NOVOCURE LIMITED23.93%9 540
PENUMBRA, INC.12.58%9 511
MASIMO CORPORATION15.84%9 009
SHOCKWAVE MEDICAL, INC.-5.34%6 789
GETINGE AB6.70%6 091